NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Highlight Therapeutics

Highlight Therapeutics

Private
PaternaHealthcare & Life Scienceshttps://www.highlighttherapeutics.com/

Last Round

Growth Equity

Sep 16, 2025

Total Funding Raised

$44.67M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Highlight Therapeutics is a biopharmaceutical company that develops RNA-based immuno-oncology therapies designed to stimulate the immune system and enhance anti-tumor responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

immuno-oncologyRNA therapyBO-112double-stranded RNAdsRNAcold to hot tumorscheckpoint inhibitor combinationsolid tumor treatmentintra-lesional therapycancer immunotherapyviral mimicryinnate immune system activationtumor microenvironment modulationdermato-oncologymelanoma treatmentpharma licensingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Highlight Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Highlight Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Highlight Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquitySep 16, 2025
Series BFeb 5, 2021

Key People

Founding team and executive leadership

MERCEDES DIZ

CEO And Member Of The Board

Executive Team

Highlight Therapeutics Investors

Notable investors and investment history

Highlight Therapeutics investors
InvestorRounds
Advent Life SciencesSeries B
GED CapitalGrowth Equity
Buenavista Equity PartnersGrowth Equity
Center for Technological Development and InnovationSeries B
Columbus Venture PartnersGrowth Equity, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 16, 2025

    $18M raised in a VC Round.

  • Sep 4, 2025

    Abel Riera appointed as new Chief Business Officer.

Highlight Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Highlight Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Highlight Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPaterna
Employee Range19
Year Founded2013
Last FundingSep 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.